APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Distress Syndrome

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.

Selected research

Market Analysis & Forecast

Global Respiratory Distress Syndrome Market Analysis and Forecast 2026-2032

20 December 2025197 pages

Choose your research edition.

Industry ResearchRespiratory Distress Syndrome Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Distress Syndrome Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Respiratory Distress Syndrome Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Distress Syndrome Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Distress Syndrome Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.

North America is the largest consumption place, with a consumption market share nearly 33% . Following North America, China is the second largest consumption place with the consumption market share of 26%.The key manufacturers are Chiesi Farmaceutici, CR-Double Crane, ONY Biotech, AbbVie, Yuhan Corporation, JW Pharmaceuticals, Noargen etc. Top 3 companies occupied about 85% market share.

Report Includes

Read the full market overview

This report presents an overview of global market for Respiratory Distress Syndrome, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Respiratory Distress Syndrome, also provides the revenue of main regions and countries. Of the upcoming market potential for Respiratory Distress Syndrome, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Respiratory Distress Syndrome revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Respiratory Distress Syndrome market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Respiratory Distress Syndrome revenue, projected growth trends, production technology, application and end-user industry.

Respiratory Distress Syndrome Segment by Company

Chiesi Farmaceutici

CR-Double Crane

ONY Biotech

AbbVie

Yuhan Corporation

JW Pharmaceuticals

Noargen

Respiratory Distress Syndrome Segment by Type

Poractant Alfa

Beractant

Calfactant

Others

Respiratory Distress Syndrome Segment by Application

Very Preterm Infants

Moderate to Late Preterm Infants

Others

Respiratory Distress Syndrome Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Distress Syndrome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Distress Syndrome and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Distress Syndrome.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Respiratory Distress Syndrome in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Respiratory Distress Syndrome company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Respiratory Distress Syndrome revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Respiratory Distress Syndrome Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Poractant Alfa Major Player Table 3. Beractant Major Player Table 4. Calfactant Major Player Table 5. Others Major Player Table 6. Global Respiratory Distress Syndrome Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Very Preterm Infants Major Player Table 8. Moderate to Late Preterm Infants Major Player Table 9. Others Major Player Table 10. Respiratory Distress Syndrome Industry Trends Table 11. Respiratory Distress Syndrome Industry Drivers Table 12. Respiratory Distress Syndrome Industry Opportunities and Challenges Table 13. Respiratory Distress Syndrome Industry Restraints Table 14. Global Respiratory Distress Syndrome Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Respiratory Distress Syndrome Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Respiratory Distress Syndrome Market Share by Region (2021-2026) Table 17. Global Respiratory Distress Syndrome Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Respiratory Distress Syndrome Market Share by Region (2027-2032) Table 19. Global Respiratory Distress Syndrome Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Respiratory Distress Syndrome Revenue Market Share by Players (2021-2026) Table 21. Global Respiratory Distress Syndrome Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Respiratory Distress Syndrome Key Players Headquarters & Area Served Table 23. Global Respiratory Distress Syndrome Players, Product Type & Application Table 24. Global Respiratory Distress Syndrome Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Respiratory Distress Syndrome by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Respiratory Distress Syndrome Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Respiratory Distress Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Respiratory Distress Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Respiratory Distress Syndrome Revenue Market Share by Type (2021-2026) Table 31. Global Respiratory Distress Syndrome Revenue Market Share by Type (2027-2032) Table 32. Global Respiratory Distress Syndrome Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Respiratory Distress Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Respiratory Distress Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Respiratory Distress Syndrome Revenue Market Share by Application (2021-2026) Table 36. Global Respiratory Distress Syndrome Revenue Market Share by Application (2027-2032) Table 37. Chiesi Farmaceutici Company Information Table 38. Chiesi Farmaceutici Business Overview Table 39. Chiesi Farmaceutici Respiratory Distress Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Chiesi Farmaceutici Respiratory Distress Syndrome Product Portfolio Table 41. Chiesi Farmaceutici Recent Development Table 42. CR-Double Crane Company Information Table 43. CR-Double Crane Business Overview Table 44. CR-Double Crane Respiratory Distress Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. CR-Double Crane Respiratory Distress Syndrome Product Portfolio Table 46. CR-Double Crane Recent Development Table 47. ONY Biotech Company Information Table 48. ONY Biotech Business Overview Table 49. ONY Biotech Respiratory Distress Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. ONY Biotech Respiratory Distress Syndrome Product Portfolio Table 51. ONY Biotech Recent Development Table 52. AbbVie Company Information Table 53. AbbVie Business Overview Table 54. AbbVie Respiratory Distress Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. AbbVie Respiratory Distress Syndrome Product Portfolio Table 56. AbbVie Recent Development Table 57. Yuhan Corporation Company Information Table 58. Yuhan Corporation Business Overview Table 59. Yuhan Corporation Respiratory Distress Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Yuhan Corporation Respiratory Distress Syndrome Product Portfolio Table 61. Yuhan Corporation Recent Development Table 62. JW Pharmaceuticals Company Information Table 63. JW Pharmaceuticals Business Overview Table 64. JW Pharmaceuticals Respiratory Distress Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. JW Pharmaceuticals Respiratory Distress Syndrome Product Portfolio Table 66. JW Pharmaceuticals Recent Development Table 67. Noargen Company Information Table 68. Noargen Business Overview Table 69. Noargen Respiratory Distress Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Noargen Respiratory Distress Syndrome Product Portfolio Table 71. Noargen Recent Development Table 72. North America Respiratory Distress Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 73. North America Respiratory Distress Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 74. North America Respiratory Distress Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 75. North America Respiratory Distress Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 76. North America Respiratory Distress Syndrome Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 77. North America Respiratory Distress Syndrome Revenue by Country (2021-2026) & (US$ Million) Table 78. North America Respiratory Distress Syndrome Revenue by Country (US$ Million) & (2027-2032) Table 79. Europe Respiratory Distress Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 80. Europe Respiratory Distress Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 81. Europe Respiratory Distress Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 82. Europe Respiratory Distress Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 83. Europe Respiratory Distress Syndrome Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 84. Europe Respiratory Distress Syndrome Revenue by Country (2021-2026) & (US$ Million) Table 85. Europe Respiratory Distress Syndrome Revenue by Country (US$ Million) & (2027-2032) Table 86. China Respiratory Distress Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 87. China Respiratory Distress Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 88. China Respiratory Distress Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 89. China Respiratory Distress Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 90. Asia Respiratory Distress Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 91. Asia Respiratory Distress Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 92. Asia Respiratory Distress Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 93. Asia Respiratory Distress Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 94. Asia Respiratory Distress Syndrome Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 95. Asia Respiratory Distress Syndrome Revenue by Region (US$ Million) & (2021-2026) Table 96. Asia Respiratory Distress Syndrome Revenue by Region (US$ Million) & (2027-2032) Table 97. SAMEA Respiratory Distress Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 98. SAMEA Respiratory Distress Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 99. SAMEA Respiratory Distress Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 100. SAMEA Respiratory Distress Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 101. SAMEA Respiratory Distress Syndrome Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. SAMEA Respiratory Distress Syndrome Revenue by Country (2021-2026) & (US$ Million) Table 103. SAMEA Respiratory Distress Syndrome Revenue by Country (US$ Million) & (2027-2032) Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Respiratory Distress Syndrome Image Figure 2. Global Respiratory Distress Syndrome Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Distress Syndrome Market Size Share 2021 VS 2025 VS 2032 Figure 4. Poractant Alfa Image Figure 5. Beractant Image Figure 6. Calfactant Image Figure 7. Others Image Figure 8. Global Respiratory Distress Syndrome Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Respiratory Distress Syndrome Market Size Share 2021 VS 2025 VS 2032 Figure 10. Very Preterm Infants Image Figure 11. Moderate to Late Preterm Infants Image Figure 12. Others Image Figure 13. Global Respiratory Distress Syndrome Market Size (US$ Million) & (2021-2032) Figure 14. Global Respiratory Distress Syndrome Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Respiratory Distress Syndrome Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Respiratory Distress Syndrome Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Respiratory Distress Syndrome Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Respiratory Distress Syndrome Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Respiratory Distress Syndrome Revenue Market Share by Type (2021-2032) Figure 21. Global Respiratory Distress Syndrome Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Respiratory Distress Syndrome Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Respiratory Distress Syndrome Revenue Market Share by Application (2021-2032) Figure 24. North America Respiratory Distress Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Respiratory Distress Syndrome Revenue Share by Type (2021-2032) Figure 26. North America Respiratory Distress Syndrome Revenue Share by Application (2021-2032) Figure 27. North America Respiratory Distress Syndrome Revenue Share by Country (2021-2032) Figure 28. United States Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Respiratory Distress Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Respiratory Distress Syndrome Revenue Share by Type (2021-2032) Figure 33. Europe Respiratory Distress Syndrome Revenue Share by Application (2021-2032) Figure 34. Europe Respiratory Distress Syndrome Revenue Share by Country (2021-2032) Figure 35. Germany Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Respiratory Distress Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Respiratory Distress Syndrome Revenue Share by Type (2021-2032) Figure 45. China Respiratory Distress Syndrome Revenue Share by Application (2021-2032) Figure 46. Asia Respiratory Distress Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Respiratory Distress Syndrome Revenue Share by Type (2021-2032) Figure 48. Asia Respiratory Distress Syndrome Revenue Share by Application (2021-2032) Figure 49. Asia Respiratory Distress Syndrome Revenue Share by Region (2021-2032) Figure 50. Japan Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Respiratory Distress Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Respiratory Distress Syndrome Revenue Share by Type (2021-2032) Figure 58. SAMEA Respiratory Distress Syndrome Revenue Share by Application (2021-2032) Figure 59. SAMEA Respiratory Distress Syndrome Revenue Share by Country (2021-2032) Figure 60. Brazil Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Respiratory Distress Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Poractant Alfa
  • Beractant
  • Calfactant
  • Others
Applications
  • Very Preterm Infants
  • Moderate to Late Preterm Infants
  • Others
Companies covered
  • Chiesi Farmaceutici
  • CR-Double Crane
  • ONY Biotech
  • AbbVie
  • Yuhan Corporation
  • JW Pharmaceuticals
  • Noargen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Respiratory Distress Syndrome Market by Type
  3. 1.2.1 Global Respiratory Distress Syndrome Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Poractant Alfa
  5. 1.2.3 Beractant
  6. 1.2.4 Calfactant
  7. 1.2.5 Others
  8. 1.3 Respiratory Distress Syndrome Market by Application
  9. 1.3.1 Global Respiratory Distress Syndrome Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Very Preterm Infants
  11. 1.3.3 Moderate to Late Preterm Infants
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Respiratory Distress Syndrome Market Dynamics
  1. 2.1 Respiratory Distress Syndrome Industry Trends
  2. 2.2 Respiratory Distress Syndrome Industry Drivers
  3. 2.3 Respiratory Distress Syndrome Industry Opportunities and Challenges
  4. 2.4 Respiratory Distress Syndrome Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Respiratory Distress Syndrome Market Perspective (2021-2032)
  2. 3.2 Global Respiratory Distress Syndrome Growth Trends by Region
  3. 3.2.1 Global Respiratory Distress Syndrome Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Respiratory Distress Syndrome Market Size by Region (2021-2026)
  5. 3.2.3 Global Respiratory Distress Syndrome Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Respiratory Distress Syndrome Revenue by Players
  2. 4.1.1 Global Respiratory Distress Syndrome Revenue by Players (2021-2026)
  3. 4.1.2 Global Respiratory Distress Syndrome Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Respiratory Distress Syndrome Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Respiratory Distress Syndrome Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Respiratory Distress Syndrome Key Players Headquarters & Area Served
  7. 4.4 Global Respiratory Distress Syndrome Players, Product Type & Application
  8. 4.5 Global Respiratory Distress Syndrome Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Respiratory Distress Syndrome Market CR5 and HHI
  11. 4.6.3 2025 Respiratory Distress Syndrome Tier 1, Tier 2, and Tier 3
5 Respiratory Distress Syndrome Market Size by Type
  1. 5.1 Global Respiratory Distress Syndrome Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Respiratory Distress Syndrome Revenue by Type (2021-2032)
  3. 5.3 Global Respiratory Distress Syndrome Revenue Market Share by Type (2021-2032)
6 Respiratory Distress Syndrome Market Size by Application
  1. 6.1 Global Respiratory Distress Syndrome Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Respiratory Distress Syndrome Revenue by Application (2021-2032)
  3. 6.3 Global Respiratory Distress Syndrome Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Chiesi Farmaceutici
  2. 7.1.1 Chiesi Farmaceutici Company Information
  3. 7.1.2 Chiesi Farmaceutici Business Overview
  4. 7.1.3 Chiesi Farmaceutici Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Chiesi Farmaceutici Respiratory Distress Syndrome Product Portfolio
  6. 7.1.5 Chiesi Farmaceutici Recent Developments
  7. 7.2 CR-Double Crane
  8. 7.2.1 CR-Double Crane Company Information
  9. 7.2.2 CR-Double Crane Business Overview
  10. 7.2.3 CR-Double Crane Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  11. 7.2.4 CR-Double Crane Respiratory Distress Syndrome Product Portfolio
  12. 7.2.5 CR-Double Crane Recent Developments
  13. 7.3 ONY Biotech
  14. 7.3.1 ONY Biotech Company Information
  15. 7.3.2 ONY Biotech Business Overview
  16. 7.3.3 ONY Biotech Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  17. 7.3.4 ONY Biotech Respiratory Distress Syndrome Product Portfolio
  18. 7.3.5 ONY Biotech Recent Developments
  19. 7.4 AbbVie
  20. 7.4.1 AbbVie Company Information
  21. 7.4.2 AbbVie Business Overview
  22. 7.4.3 AbbVie Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AbbVie Respiratory Distress Syndrome Product Portfolio
  24. 7.4.5 AbbVie Recent Developments
  25. 7.5 Yuhan Corporation
  26. 7.5.1 Yuhan Corporation Company Information
  27. 7.5.2 Yuhan Corporation Business Overview
  28. 7.5.3 Yuhan Corporation Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Yuhan Corporation Respiratory Distress Syndrome Product Portfolio
  30. 7.5.5 Yuhan Corporation Recent Developments
  31. 7.6 JW Pharmaceuticals
  32. 7.6.1 JW Pharmaceuticals Company Information
  33. 7.6.2 JW Pharmaceuticals Business Overview
  34. 7.6.3 JW Pharmaceuticals Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  35. 7.6.4 JW Pharmaceuticals Respiratory Distress Syndrome Product Portfolio
  36. 7.6.5 JW Pharmaceuticals Recent Developments
  37. 7.7 Noargen
  38. 7.7.1 Noargen Company Information
  39. 7.7.2 Noargen Business Overview
  40. 7.7.3 Noargen Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Noargen Respiratory Distress Syndrome Product Portfolio
  42. 7.7.5 Noargen Recent Developments
8 North America
  1. 8.1 North America Respiratory Distress Syndrome Revenue (2021-2032)
  2. 8.2 North America Respiratory Distress Syndrome Revenue by Type (2021-2032)
  3. 8.2.1 North America Respiratory Distress Syndrome Revenue by Type (2021-2026)
  4. 8.2.2 North America Respiratory Distress Syndrome Revenue by Type (2027-2032)
  5. 8.3 North America Respiratory Distress Syndrome Revenue Share by Type (2021-2032)
  6. 8.4 North America Respiratory Distress Syndrome Revenue by Application (2021-2032)
  7. 8.4.1 North America Respiratory Distress Syndrome Revenue by Application (2021-2026)
  8. 8.4.2 North America Respiratory Distress Syndrome Revenue by Application (2027-2032)
  9. 8.5 North America Respiratory Distress Syndrome Revenue Share by Application (2021-2032)
  10. 8.6 North America Respiratory Distress Syndrome Revenue by Country
  11. 8.6.1 North America Respiratory Distress Syndrome Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Respiratory Distress Syndrome Revenue by Country (2021-2026)
  13. 8.6.3 North America Respiratory Distress Syndrome Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Respiratory Distress Syndrome Revenue (2021-2032)
  2. 9.2 Europe Respiratory Distress Syndrome Revenue by Type (2021-2032)
  3. 9.2.1 Europe Respiratory Distress Syndrome Revenue by Type (2021-2026)
  4. 9.2.2 Europe Respiratory Distress Syndrome Revenue by Type (2027-2032)
  5. 9.3 Europe Respiratory Distress Syndrome Revenue Share by Type (2021-2032)
  6. 9.4 Europe Respiratory Distress Syndrome Revenue by Application (2021-2032)
  7. 9.4.1 Europe Respiratory Distress Syndrome Revenue by Application (2021-2026)
  8. 9.4.2 Europe Respiratory Distress Syndrome Revenue by Application (2027-2032)
  9. 9.5 Europe Respiratory Distress Syndrome Revenue Share by Application (2021-2032)
  10. 9.6 Europe Respiratory Distress Syndrome Revenue by Country
  11. 9.6.1 Europe Respiratory Distress Syndrome Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Respiratory Distress Syndrome Revenue by Country (2021-2026)
  13. 9.6.3 Europe Respiratory Distress Syndrome Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Respiratory Distress Syndrome Revenue (2021-2032)
  2. 10.2 China Respiratory Distress Syndrome Revenue by Type (2021-2032)
  3. 10.2.1 China Respiratory Distress Syndrome Revenue by Type (2021-2026)
  4. 10.2.2 China Respiratory Distress Syndrome Revenue by Type (2027-2032)
  5. 10.3 China Respiratory Distress Syndrome Revenue Share by Type (2021-2032)
  6. 10.4 China Respiratory Distress Syndrome Revenue by Application (2021-2032)
  7. 10.4.1 China Respiratory Distress Syndrome Revenue by Application (2021-2026)
  8. 10.4.2 China Respiratory Distress Syndrome Revenue by Application (2027-2032)
  9. 10.5 China Respiratory Distress Syndrome Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Respiratory Distress Syndrome Revenue (2021-2032)
  2. 11.2 Asia Respiratory Distress Syndrome Revenue by Type (2021-2032)
  3. 11.2.1 Asia Respiratory Distress Syndrome Revenue by Type (2021-2026)
  4. 11.2.2 Asia Respiratory Distress Syndrome Revenue by Type (2027-2032)
  5. 11.3 Asia Respiratory Distress Syndrome Revenue Share by Type (2021-2032)
  6. 11.4 Asia Respiratory Distress Syndrome Revenue by Application (2021-2032)
  7. 11.4.1 Asia Respiratory Distress Syndrome Revenue by Application (2021-2026)
  8. 11.4.2 Asia Respiratory Distress Syndrome Revenue by Application (2027-2032)
  9. 11.5 Asia Respiratory Distress Syndrome Revenue Share by Application (2021-2032)
  10. 11.6 Asia Respiratory Distress Syndrome Revenue by Country
  11. 11.6.1 Asia Respiratory Distress Syndrome Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Respiratory Distress Syndrome Revenue by Country (2021-2026)
  13. 11.6.3 Asia Respiratory Distress Syndrome Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Respiratory Distress Syndrome Revenue (2021-2032)
  2. 12.2 SAMEA Respiratory Distress Syndrome Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Respiratory Distress Syndrome Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Respiratory Distress Syndrome Revenue by Type (2027-2032)
  5. 12.3 SAMEA Respiratory Distress Syndrome Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Respiratory Distress Syndrome Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Respiratory Distress Syndrome Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Respiratory Distress Syndrome Revenue by Application (2027-2032)
  9. 12.5 SAMEA Respiratory Distress Syndrome Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Respiratory Distress Syndrome Revenue by Country
  11. 12.6.1 SAMEA Respiratory Distress Syndrome Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Respiratory Distress Syndrome Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Respiratory Distress Syndrome Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst